Cargando…
Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus
The recent emergence of antibiotic-resistant bacteria requires the development of new antibiotics or new agents capable of enhancing antibiotic activity. This study evaluated the antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobac...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538184/ https://www.ncbi.nlm.nih.gov/pubmed/31136634 http://dx.doi.org/10.1371/journal.pone.0217504 |
_version_ | 1783422148968185856 |
---|---|
author | Saito, Hiroaki Sakakibara, Yumi Sakata, Ayumi Kurashige, Rie Murakami, Daisuke Kageshima, Hiroki Saito, Akira Miyazaki, Yasunari |
author_facet | Saito, Hiroaki Sakakibara, Yumi Sakata, Ayumi Kurashige, Rie Murakami, Daisuke Kageshima, Hiroki Saito, Akira Miyazaki, Yasunari |
author_sort | Saito, Hiroaki |
collection | PubMed |
description | The recent emergence of antibiotic-resistant bacteria requires the development of new antibiotics or new agents capable of enhancing antibiotic activity. This study evaluated the antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus (MRSA), which should resolve the problem of antibiotic-resistant bacteria. Bactericidal tests showed that LYZOX killed 50% more P. aeruginosa (NBRC 13275), A. baumannii and MRSA than the control treatment after 60 min. In addition, LYZOX was shown to inhibit the growth of P. aeruginosa (NBRC 13275 and PAO1), A. baumannii and MRSA better than its components. To elucidate the antibacterial mechanism of LYZOX, we performed cell membrane integrity assays, N-phenyl-1-naphthylamine assays, 2-nitrophenyl β-D-galactopyranoside assays and confocal laser scanning microscopy. These results showed that LYZOX affected bacterial cell walls and increased the permeability of the outer membrane and the plasma membrane. Furthermore, each type of bacteria treated with LYZOX was observed by electron microscopy. Electron micrographs revealed that these bacteria had the morphological features of both lysozyme-treated and chitosan oligosaccharide-treated bacteria and that LYZOX destroyed bacterial cell walls, which caused the release of intracellular contents from cells. An acquired drug resistance test revealed that these bacteria were not able to acquire resistance to LYZOX. The hemolytic toxicity test demonstrated the low hemolytic activity of LYZOX. In conclusion, LYZOX exhibited antibacterial activity and low drug resistance in the presence of P. aeruginosa, A. baumannii and MRSA and showed low hemolytic toxicity. LYZOX affected bacterial membranes, leading to membrane disruption and the release of intracellular contents and consequent bacterial cell death. LYZOX may serve as a novel candidate drug that could be used for the control of refractory infections. |
format | Online Article Text |
id | pubmed-6538184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-65381842019-06-05 Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus Saito, Hiroaki Sakakibara, Yumi Sakata, Ayumi Kurashige, Rie Murakami, Daisuke Kageshima, Hiroki Saito, Akira Miyazaki, Yasunari PLoS One Research Article The recent emergence of antibiotic-resistant bacteria requires the development of new antibiotics or new agents capable of enhancing antibiotic activity. This study evaluated the antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus (MRSA), which should resolve the problem of antibiotic-resistant bacteria. Bactericidal tests showed that LYZOX killed 50% more P. aeruginosa (NBRC 13275), A. baumannii and MRSA than the control treatment after 60 min. In addition, LYZOX was shown to inhibit the growth of P. aeruginosa (NBRC 13275 and PAO1), A. baumannii and MRSA better than its components. To elucidate the antibacterial mechanism of LYZOX, we performed cell membrane integrity assays, N-phenyl-1-naphthylamine assays, 2-nitrophenyl β-D-galactopyranoside assays and confocal laser scanning microscopy. These results showed that LYZOX affected bacterial cell walls and increased the permeability of the outer membrane and the plasma membrane. Furthermore, each type of bacteria treated with LYZOX was observed by electron microscopy. Electron micrographs revealed that these bacteria had the morphological features of both lysozyme-treated and chitosan oligosaccharide-treated bacteria and that LYZOX destroyed bacterial cell walls, which caused the release of intracellular contents from cells. An acquired drug resistance test revealed that these bacteria were not able to acquire resistance to LYZOX. The hemolytic toxicity test demonstrated the low hemolytic activity of LYZOX. In conclusion, LYZOX exhibited antibacterial activity and low drug resistance in the presence of P. aeruginosa, A. baumannii and MRSA and showed low hemolytic toxicity. LYZOX affected bacterial membranes, leading to membrane disruption and the release of intracellular contents and consequent bacterial cell death. LYZOX may serve as a novel candidate drug that could be used for the control of refractory infections. Public Library of Science 2019-05-28 /pmc/articles/PMC6538184/ /pubmed/31136634 http://dx.doi.org/10.1371/journal.pone.0217504 Text en © 2019 Saito et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Saito, Hiroaki Sakakibara, Yumi Sakata, Ayumi Kurashige, Rie Murakami, Daisuke Kageshima, Hiroki Saito, Akira Miyazaki, Yasunari Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus |
title | Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus |
title_full | Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus |
title_fullStr | Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus |
title_full_unstemmed | Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus |
title_short | Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus |
title_sort | antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (lyzox) against pseudomonas aeruginosa, acinetobacter baumannii and methicillin-resistant staphylococcus aureus |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538184/ https://www.ncbi.nlm.nih.gov/pubmed/31136634 http://dx.doi.org/10.1371/journal.pone.0217504 |
work_keys_str_mv | AT saitohiroaki antibacterialactivityoflysozymechitosanoligosaccharideconjugateslyzoxagainstpseudomonasaeruginosaacinetobacterbaumanniiandmethicillinresistantstaphylococcusaureus AT sakakibarayumi antibacterialactivityoflysozymechitosanoligosaccharideconjugateslyzoxagainstpseudomonasaeruginosaacinetobacterbaumanniiandmethicillinresistantstaphylococcusaureus AT sakataayumi antibacterialactivityoflysozymechitosanoligosaccharideconjugateslyzoxagainstpseudomonasaeruginosaacinetobacterbaumanniiandmethicillinresistantstaphylococcusaureus AT kurashigerie antibacterialactivityoflysozymechitosanoligosaccharideconjugateslyzoxagainstpseudomonasaeruginosaacinetobacterbaumanniiandmethicillinresistantstaphylococcusaureus AT murakamidaisuke antibacterialactivityoflysozymechitosanoligosaccharideconjugateslyzoxagainstpseudomonasaeruginosaacinetobacterbaumanniiandmethicillinresistantstaphylococcusaureus AT kageshimahiroki antibacterialactivityoflysozymechitosanoligosaccharideconjugateslyzoxagainstpseudomonasaeruginosaacinetobacterbaumanniiandmethicillinresistantstaphylococcusaureus AT saitoakira antibacterialactivityoflysozymechitosanoligosaccharideconjugateslyzoxagainstpseudomonasaeruginosaacinetobacterbaumanniiandmethicillinresistantstaphylococcusaureus AT miyazakiyasunari antibacterialactivityoflysozymechitosanoligosaccharideconjugateslyzoxagainstpseudomonasaeruginosaacinetobacterbaumanniiandmethicillinresistantstaphylococcusaureus |